<DOC>
	<DOCNO>NCT01425008</DOCNO>
	<brief_summary>This phase 1 , multicenter , nonrandomized , open-label , dose escalation study . The study conduct 2 stage , Dose Escalation Dose Expansion . The Dose Escalation phase include patient solid tumor ( include melanoma ) fail candidate standard therapy approve therapy available . The Dose Expansion phase include patient metastatic melanoma .</brief_summary>
	<brief_title>Study MLN2480 Patients With Relapsed Refractory Solid Tumors Followed Dose Expansion Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Informed consent Male female patient 18 year old Dose Escalation phase : Patients solid tumor ( include melanoma ) fail candidate standard therapy approve therapy available Dose Expansion phase : Metastatic melanoma ( locally advance metastatic melanoma ) Dose Expansion phase : At least 1 measurable lesion treat previously radiotherapy . A newly arise lesion previously irradiate field acceptable For patient undergo biopsy procedure : Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) must within normal range Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Adequate tissue sample either archival formalinfixed paraffinembedded ( FFPE ) tumor tissue new biopsy tumor Previous chemotherapy , immunotherapy , hormone therapy must complete least 4 week prior administration MLN2480 radiation must complete least 3 week prior administration MLN2480 ; associate toxicity must resolve ≤ Grade 1 Expected survival time least 3 month opinion investigator Patients hypo hyperthyroidism Ability swallow retain oral medication Female patient post menopausal least 1 year , surgically sterile , agree practice 2 effective method contraception 3 month last dose study drug agree practice true abstinence Male patient , even surgically sterilize , agree practice effective barrier contraception 3 month last dose alisertib agree practice true abstinence Exclusion Criteria History major disease might interfere safe protocol participation Dose Expansion phase : Previous treatment RAF MEK inhibitor Laboratory value specify study protocol Current enrollment investigational treatment study Evidence current uncontrolled cardiovascular condition within past 6 month Prior investigational agent malignant nonmalignant disease within 4 week prior Day 1 Active hepatitis human immunodeficiency virus ( HIV ) infection Active bacterial viral infection Female patient pregnant currently breastfeed Major surgery within 28 day Day 1 Refractory nausea vomiting , malabsorption , significant bowel stomach resection Inability comply study requirement Other unspecified reason , opinion investigator Millennium , make patient unsuitable enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>